English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Acute myeloid leukemia (AML), the most common type of leukemia in adults, is characterized by an uncontrolled proliferation of immature progenitor cells which results in the rapid increase of abnormal cells in blood as well as the bone marrow. Although AML is a fairly rare disorder, accounting for around 0.9% of all cancers diagnosed in the USA during 2012, its crude incidence rate keeps increasing in USA (from 3.4 (per 100,000) in 2004 to 5.1 in 2013) and South Korea (from 1.87 in 1999 to 2.50 in 2012). With its increasing incidence with ages, AML steadily raise medical awareness due to its high relapse and poor prognosis. Specifically, approximately 75% of patients with AML relapse after primary therapy without achieving complete remission, and AML patients showed the shortest 5-year survival rate of 24% among acute leukemia. In particular, 97% of older AML patients aged 70–79 years will die in the subsequent five years. However, the underlying pathophysiology of poor survival and frequent Rhus Verniciflua Stokes Extract Suppresses Expression of Metalloproteinases, iNOS and COX-2 in THP-1 Cells Via Inhibiting NF-κB and MAPK Phosphorylation

daehan han'yi hag'hoeji/journal of korean medicine

Rhus Verniciflua Stokes Extract Suppresses Expression of Metalloproteinases, iNOS and COX-2 in THP-1 Cells Via Inhibiting NF-κB and MAPK Phosphorylation